Sleep Better Columbus is now offering FDA-cleared oral appliance therapy for patients diagnosed with mild to moderate ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Topline data were announced from a phase 3 trial evaluating AD109 (aroxybutynin 2.5mg/atomoxetine 75mg) in participants with obstructive sleep apnea.

Explore the rising trend of mouth taping during sleep, analyzing its potential risks and minimal benefits for breathing and ...

A recent post-hoc analysis of the SURMOUNT-OSA trials revealed that tirzepatide significantly improves obstructive sleep ...

If you struggle with 'mouth breathing' while you sleep, from the occasional snore or full-blown obstructive sleep apnea, you ...

Apnimed’s star sleep apnea asset has hit the latest landmark on its march down victory road. | Apnimed’s star sleep apnea ...

CI Insights From Zepbound to AD109, pharma innovation is reshaping Obstructive Sleep Apnea. Discover key players, C ...

“REM sleep is when your brain does some of its most important cleanup and memory storage work,” said co-corresponding author ...

Obstructive Sleep Apnea (OSA) remains a widespread yet under-treated condition, affecting millions globally. Traditional treatments such as CPAP therapy, w | Drug Discovery And Development ...

At 12 months of therapy, the treatment arm responder rate was 65% with responders defined as those who realized at least a 50% improvement from the baseline apnea-hypopnea index (AHI) and an AHI ...

Greater obstructive sleep apnea (OSA)-related hypoxemia is associated with frontoparietal cerebrovascular pathology, which is linked to reduced medial temporal lobe (MTL) integrity and impaired ...